• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC HEART VALVES DIVISION EVOLUT R TRANSCATHETER AORTIC VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC HEART VALVES DIVISION EVOLUT R TRANSCATHETER AORTIC VALVE; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV Back to Search Results
Model Number EVOLUTR-29
Device Problem Insufficient Information (3190)
Patient Problems Chest Pain (1776); Myocardial Infarction (1969); Pleural Effusion (2010); Pulmonary Edema (2020); Heart Failure/Congestive Heart Failure (4446); Swelling/ Edema (4577)
Event Date 12/12/2021
Event Type  Injury  
Manufacturer Narrative
Product analysis: the device remains implanted, therefore no product analysis can be performed.Conclusion: without return of the product, no definitive conclusions could be drawn regarding the clinical observation.Select patient information cannot be included in regulatory report due to regional privacy regulations.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Event Description
Medtronic received information that approximately 4 years and 2 months following the implant of this transcatheter bioprosthetic valve, the patient presented at the emergency department with report of chest pressure that had occurred for approximately 6 hours.While hospitalized, an electrocardiogram (ecg) identified non-specific st depression and a rising troponin measured 0.0, 0.10, 0.11 and 0.07.A non-st elevation myocardial infarction (nstemi) was reported.2+ bilateral pedal edema note with report of congestive heart failure (chf).The following day xarelto was held, aspirin, plavix and enoxaparin were administered (therapeutic anti-coagulation).Ecg monitoring continued.Repeat troponin and chest x-ray were performed within 24 hours and were trended down.Regarding the nstemi, the patient became completely asymptomatic and stable.The nstemi was considered resolved 4 days following onset.Additionally, during the hospitalization, the patient was treated for congestive heart failure.A chest x-ray showed clearing with note of small bilateral pleural effusions again with bibasal atelectasis.There was mild diffuse interstitial prominence throughout both lungs predominantly of right lung.As reported, these could represent chronic interstitial changes verse mild interstitial pulmonary edema.Two days following onset of chf, the chest x-ray noted resolving chf.Vascular redistribution noted and improved.Blunting of the costophrenic angles was again noted but had improved on the left side.Lung parenchymal changes at the right lung base were similar as previous.The patient was discharged home.  of note, the physician reported that nstemi and congestive heart failure were considered possibly related to the valve.No further information was provided.
 
Event Description
Additional information was received that an echocardiogram was performed approximately three years, nine months following valve implant and the valve was reported to be functioning as expected, no issues were observed.During the patient's hospital admission approximately 6 months later, it was noted the chf may have triggered the st-elevation and troponin increase.Per the physician, an exacerbation of chf could not be ruled out as an echocardiogram was not performed and the valve was not investigated to determine whether it was still functioning as expected.The physician indicated the patient had underlying heart disease which required the transcatheter bioprosthetic valve implant.No additional adverse patient effects were reported.
 
Manufacturer Narrative
Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EVOLUT R TRANSCATHETER AORTIC VALVE
Type of Device
AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV
Manufacturer (Section D)
MEDTRONIC HEART VALVES DIVISION
1851 e deere ave
santa ana CA 92705
Manufacturer (Section G)
MEDTRONIC HEART VALVES DIVISION
1851 e deere ave
santa ana CA 92705
Manufacturer Contact
alison sweeney
parkmore business park west
galway 
EI  
091708096
MDR Report Key15874564
MDR Text Key304420649
Report Number2025587-2022-03332
Device Sequence Number1
Product Code NPT
Combination Product (y/n)N
Reporter Country CodeCA
PMA/PMN Number
P130021
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Study,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 01/19/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date08/29/2018
Device Model NumberEVOLUTR-29
Device Catalogue NumberEVOLUTR-29
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 11/21/2022
Initial Date FDA Received11/28/2022
Supplement Dates Manufacturer Received12/20/2022
Supplement Dates FDA Received01/19/2023
Date Device Manufactured09/18/2017
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Hospitalization;
-
-